Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2010

View Archived Issues

FIBREX Medical discloses novel cell adhesion inhibitors

Roche discovers novel NS5B inhibitors for HCV infection

Abbott describes new indole and indoline derivatives with neurotrophic activity

NeuroSearch identifies novel potassium channel modulators

Biotechnology Research claims new PGE2, NMDA and MC receptor antagonists

Data on vipadenant warrant further development in moderate- to late-stage PD patients

Quinacrine does not extend survival in sporadic Creutzfeldt-Jakob disease

Ongoing tacrolimus treatment beneficial for atopic dermatitis

ONO-8539 for overactive bladder well tolerated in healthy adults

Decline of mGlu5 receptor binding as a marker of early Alzheimer's disease

First phase III trial of ThromboGenics' microplasmin for eye disease meets primary endpoint

Topline phase III data disclosed on Benlysta in systemic lupus erythematosus

QLT reports interim phase Ib data on QLT-091001 in Leber's congenital amaurosis

Roche advances RG-7348 for hepatitis C into the clinic

LCL-161 well tolerated in ongoing first-in-human study

SCH-900776 sensitizes cancer cells to hydroxyurea and gemcitabine

Gilead provides update on development of fixed-dose Truvada/TMC-278 regimen for HIV

Cornerstone receives FDA clearance for phase I trial of CPI-613 in hematologic malignancies

Cadence Pharmaceuticals to resubmit NDA for Ofirmev injection

EntreMed completes registered direct offering to fund clinical development of ENMD-2076

Acorda plans phase I trial of GGF2 for treatment of heart failure

European Joulferon MAA for chronic hepatitis C withdrawn

Southern Research and Vivo Biosciences sign promotion and comarketing agreement

ChromoCure and GRG sign letter of intent in merger and acquisition agreement

Elan considers dividing Elan Drug Technologies into two companies

Abbott completes tender offer to finalize acquisition of Facet Biotech

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...